Merck & Co. Inc. closed 42.70% short of its 52-week high of $134.63, which the company reached on June 25th.

Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

MoonLake Immunotherapeutics shares surged 31% after the Financial Times reported, citing unnamed sources, that the company had rejected an initial acquisition offer by Merck & Co. for more than $3 ...

Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Bill Stone, Glenview Trust Company chief investment officer, mentioned his bullish take on Merck (NYSE:MRK) during a recent ...

BIOSeedin Innovation Partnering Conference (BIOS), established in 2021, has quickly become one of the most prestigious biopharmaceutical partnering events in APAC. Hosted annually by bioSeedin, BIOS ...

Dr. Reddy's Laboratories and Alvotech have partnered to co-develop, manufacture, and commercialize a biosimilar of Keytruda ...

Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of ...

Dr. Reddy's and Alvotech collaborate to develop biosimilar to Keytruda, enhancing oncology capabilities and global reach.

Dr. Reddy's and Alvotech have partnered to co-develop a biosimilar of Keytruda, Merck's $29.5 billion cancer drug, boosting ...